Literature DB >> 19665606

Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses.

Isabella Alberini1, Elena Del Tordello, Alba Fasolo, Nigel J Temperton, Grazia Galli, Chiara Gentile, Emanuele Montomoli, Anne K Hilbert, Angelika Banzhoff, Giuseppe Del Giudice, John J Donnelly, Rino Rappuoli, Barbara Capecchi.   

Abstract

The standard serological methods present limitations for the measurement of immunity against H5N1 influenza strains. The hemagglutination inhibition (HI) assay lacks sensitivity and requires standardization, while the viral micro-neutralization (MN) assay needs handling of live virus. We produced pseudoparticles expressing hemagglutinin from clades 1 or 2 H5N1 in order to measure neutralizing antibodies in human sera after prime-boost vaccination with plain or MF59-adjuvanted H5N1 clade 1 subunit vaccines. Titers measured by pseudoparticle neutralization (PPN) assay significantly correlated with those measured by HI, single radial haemolysis or MN, with a PPN titer of 1:357 corresponding to an MN titer of 1:80. Notably, results from the PPN assay, confirm that MF59-H5N1 vaccine induces potent and long-lasting neutralizing antibody responses not only against the vaccine strain, but also against several heterologous clade 2 strains. Overall, the PPN assay represents a valid alternative to conventional serological methods for the evaluation of H5N1 vaccine immunogenicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19665606     DOI: 10.1016/j.vaccine.2009.07.079

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  26 in total

1.  MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

Authors:  Surender Khurana; Nitin Verma; Jonathan W Yewdell; Anne Katrin Hilbert; Flora Castellino; Maria Lattanzi; Giuseppe Del Giudice; Rino Rappuoli; Hana Golding
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

2.  Development of an influenza virus protein array using Sortagging technology.

Authors:  Antonia Sinisi; Maximilian Wei-Lin Popp; John M Antos; Werner Pansegrau; Silvana Savino; Mikkel Nissum; Rino Rappuoli; Hidde L Ploegh; Ludovico Buti
Journal:  Bioconjug Chem       Date:  2012-05-25       Impact factor: 4.774

3.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Authors:  Davide Corti; Amorsolo L Suguitan; Debora Pinna; Chiara Silacci; Blanca M Fernandez-Rodriguez; Fabrizia Vanzetta; Celia Santos; Catherine J Luke; Fernando J Torres-Velez; Nigel J Temperton; Robin A Weiss; Federica Sallusto; Kanta Subbarao; Antonio Lanzavecchia
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

4.  Development of a neutralization assay for influenza virus using an endpoint assessment based on quantitative reverse-transcription PCR.

Authors:  Belete Teferedegne; Andrew M Lewis; Keith Peden; Haruhiko Murata
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

5.  Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2.

Authors:  Wei Wang; Christine M Anderson; Christopher J De Feo; Min Zhuang; Hong Yang; Russell Vassell; Hang Xie; Zhiping Ye; Dorothy Scott; Carol D Weiss
Journal:  PLoS Pathog       Date:  2011-06-09       Impact factor: 6.823

Review 6.  Pseudotype-based neutralization assays for influenza: a systematic analysis.

Authors:  George William Carnell; Francesca Ferrara; Keith Grehan; Craig Peter Thompson; Nigel James Temperton
Journal:  Front Immunol       Date:  2015-04-29       Impact factor: 7.561

7.  Protection against H5N1 Influenza Virus Induced by Matrix-M Adjuvanted Seasonal Virosomal Vaccine in Mice Requires Both Antibodies and T Cells.

Authors:  Freek Cox; Matthijs Baart; Jeroen Huizingh; Jeroen Tolboom; Liesbeth Dekking; Jaap Goudsmit; Eirikur Saeland; Katarina Radošević
Journal:  PLoS One       Date:  2015-12-22       Impact factor: 3.240

8.  The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes.

Authors:  Francesca Ferrara; Eleonora Molesti; Eva Böttcher-Friebertshäuser; Giovanni Cattoli; Davide Corti; Simon D Scott; Nigel J Temperton
Journal:  J Mol Genet Med       Date:  2013-02-20

9.  An Innovative Pseudotypes-Based Enzyme-Linked Lectin Assay for the Measurement of Functional Anti-Neuraminidase Antibodies.

Authors:  Marua Prevato; Roberta Cozzi; Alfredo Pezzicoli; Anna Rita Taddei; Ilaria Ferlenghi; Avishek Nandi; Emanuele Montomoli; Ethan C Settembre; Sylvie Bertholet; Alessandra Bonci; Francois Legay
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

Review 10.  Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.

Authors:  Claudia Maria Trombetta; Daniele Perini; Stuart Mather; Nigel Temperton; Emanuele Montomoli
Journal:  Vaccines (Basel)       Date:  2014-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.